Health ❯ Healthcare

Regulatory Agencies

FDA Anvisa MHRA European Medicines Agency Food and Drug Administration Drug Approval Process ANSM Drug Safety Drug Approval ANMAT

More Than 2.5 Million Lupin Eye Drop Bottles Recalled Nationwide

The FDA classified the action as Class II because a possible foreign substance was found, requiring patients to stop using affected bottles.

Stories older than 24h

EMA Committee Recommends Revoking Tavneos Authorization

Nationwide Recall of 25 mg Chlorthalidone Covers 11,460 Bottles

FDA Approves First Generic Single‑Dose Flu Drug

More Than 370,000 Duloxetine Bottles Recalled Over Nitrosamine Contamination

Anvisa Orders Recall of Unregistered Infant Formula From Santa Catarina Compounding Pharmacy

FDA Launches Retrospective Safety Study of Mifepristone

Brazil Medical Council Bans Doctors From Using Injectable PMMA

Brazil Clears First Domestic Semaglutide Pen and Sets Price Ceiling Equal to Ozempic

MHRA Recalls Batch of Ramipril 2.5mg After Packaging Error

Mexico Issues Alert After Falsified Ozempic Lot Identified

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

Brazil Approves 24‑Hour Subcutaneous Levodopa Therapy for Advanced Parkinson

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

Pharmacal Recalls One Lot of MG217 Eczema Cream Over Staph Contamination

Makary Resigns as FDA Commissioner With Diamantas as Acting Leader

MHRA Issues Class 4 Alert Over Leaflet Errors in Milpharm Loperamide Orodispersible Tablets

Brazil Approves Yesintek as a Stelara Biosimilar for Autoimmune Diseases

MHRA Tightens Finasteride Safety Warnings, Adds Precaution for Dutasteride

Reports Say Trump Signs Off on Plan to Remove FDA Chief Marty Makary